Blog - Yseop 09月22日 23:05
Claret注资1000万欧元,Yseop加速生命科学领域生成式AI平台发展
index_new5.html
../../../zaker_core/zaker_tpl_static/wap/tpl_guoji1.html

 

Claret Capital Partners宣布向生命科学领域的生成式AI领导者Yseop投资1000万欧元,以支持其国际扩张和企业级监管内容自动化平台的开发。Yseop的旗舰产品Yseop Copilot已获礼来和诺华等制药巨头采用,能高效生成临床研究报告、患者叙述和CMC提交等复杂文档。该平台采用创新的Composite AI架构,结合大型语言模型、业务逻辑和领域规则,确保输出内容科学合规且可审计。本次融资将助力Yseop扩大市场份额,提升产品能力,并满足全球生命科学行业对精准、高效合规AI解决方案日益增长的需求。

💡 **Yseop获得Claret Capital Partners的1000万欧元增长投资**:这笔资金将显著推动Yseop的国际化进程,并加速其为生命科学行业打造的企业级生成式AI监管内容自动化平台的研发。

🚀 **Yseop Copilot在制药行业已获广泛应用**:该旗舰产品已被Eli Lilly和Novartis等领先制药公司部署,能够高效生成临床研究报告(CSRs)、患者叙述和CMC提交等复杂监管文档,显著提升内容产出的速度和一致性。

🧠 **创新的Composite AI架构确保合规与效率**:Yseop的平台采用独特的Composite AI架构,将大型语言模型与严格的业务逻辑及领域规则相结合,确保生成的监管内容在科学上准确、合规且可供审计,并能无缝集成到Microsoft Word和Veeva Vault等现有工作流程中。

📈 **本次融资旨在满足日益增长的市场需求**:Yseop计划利用这笔新资金扩大其平台的市场采用率,持续改进产品功能,并拓展全球业务,以满足生命科学领域对精准、高效且合规的AI解决方案不断增长的需求。

NEW YORK, NY – September 18 – Claret Capital Partners has announced a €10 million growth investment in Yseop, a global leader in Generative AI for life sciences. The funding will support Yseop’s international expansion and accelerate the development of its enterprise-grade platform for regulatory content automation.

Yseop’s flagship product, Yseop Copilot, is already deployed across leading pharmaceutical organizations including Eli Lilly and Novartis. The platform streamlines the creation of complex clinical and regulatory documentation such as clinical study reports (CSRs), patient narratives, and CMC submissions. This allows teams to produce high-quality, compliant content with greater speed and consistency.

Built for regulated environments, Yseop’s Composite AI architecture combines large language models with business logic and domain rules to ensure outputs are scientifically aligned, compliant, and audit-ready. Its native integration with Microsoft Word and Veeva Vault allows life sciences organizations to embed automation directly into their existing workflows.

Antony Baker, Senior Investment Director at Claret Capital Partners, said:

“We are delighted to invest in Yseop. Their team is building an exciting, highly innovative business, with a leading AI-powered platform that is helping some of the biggest names in pharma to deliver therapies faster to market. We very much look forward to being part of the growth journey from here.”

Emmanuel Walckenaer, CEO of Yseop, added:

“This investment comes at a pivotal moment for our industry. As regulatory complexity increases and timelines tighten, the need for intelligent automation is only growing. Claret’s support allows us to accelerate innovation and deliver even greater value to our customers.”

With this new funding, Yseop will continue to scale adoption, enhance product capabilities, and expand globally to meet growing demand for accurate, efficient, and compliant AI solutions across life sciences.

The post Claret Capital Partners Announces €10M Growth Funding in Yseop to Scale Generative AI Platform for Life Sciences and Pharma appeared first on Yseop.

Fish AI Reader

Fish AI Reader

AI辅助创作,多种专业模板,深度分析,高质量内容生成。从观点提取到深度思考,FishAI为您提供全方位的创作支持。新版本引入自定义参数,让您的创作更加个性化和精准。

FishAI

FishAI

鱼阅,AI 时代的下一个智能信息助手,助你摆脱信息焦虑

联系邮箱 441953276@qq.com

相关标签

Yseop Generative AI Life Sciences Pharma Regulatory Content Automation Claret Capital Partners AI Healthcare Technology 投资 生命科学 生成式AI 制药
相关文章